Short-Course Regimen for Subsequent Treatment of Pulmonary Tuberculosis: A Prospective, Randomized, Controlled Multicenter Clinical Trial in China

Publication date: Available online 6 March 2018
Source:Clinical Therapeutics
Author(s): Liping Yan, Xiaohong Kan, Limei Zhu, Kaijin Xu, Jianjun Yin, Li Jie, Yong Li, Ji Yue, Wenyu Cui, Juan Du, Lihua Wang, Shouyong Tan, Xiangao Jiang, Zhong Zeng, Shenghui Xu, Lin Wang, Yu Chen, Weiguo He, Xusheng Gao, Dapeng Bai, Chengjie Zhao, Xiaofeng Yan, Yuyin Zhu, Yumei Fan, Lanpin Xie, Aihua Deng, Qing Zhang, Heping Xiao
PurposeWe designed a prospective, multicenter, randomized, controlled study to assess a 5-month regimen compared with the standard regimen on previously treated patients with pulmonary tuberculosis (TB).MethodsWe enrolled 917 sputum smear–positive patients undergoing additional treatment in 27 major tuberculosis hospitals in China. Patients were randomly assigned to a test group (n = 626)treated with a 5-month regimen of moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide or a reference group (n = 291) treated with an 8-month regimen of isoniazid, rifampicin, and streptomycin. All patients with a favorable response were followed up for 5 years after the end of treatment.FindingsOf the study patients, 61 in the test group and 19 in the reference group had multidrug-resistant (MDR) TB. The treatment success rate in the study group was 74.12%, which was significantly higher than the 67.70% in the reference group (P = 0.04), whereas the treatment success rate of patients with MDR-TB was not significantly different between the test and reference groups (70.5% vs 63.1%, P =0.79). The adverse effects rates in the test and reference groups were 7.4% and 3.1%, respectively (P = .01). The difference in the TB recurrence rates between the group arm (9.6%) and the reference group (21.8%) was statistically significant (P < 0.001).ImplicationsThe moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide test regimen yielded higher success and lower recurrence rates than the currently recommended isoniazid, rifampicin, and streptomycin regimen, but the rate of adverse effects was higher. ClinicalTrials.gov identifier: NCT02331823.



http://ift.tt/2FqIL7Q